Understanding the role of DNMT1 SUMOylation in Acute Myeloid Leukaemia

了解 DNMT1 SUMO 化在急性髓系白血病中的作用

• 批准号: nhmrc : 2003909
• 金额: $ 63.93万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/understanding-role-dnmt1-myeloid-leukaemia/1780245
• 关键词: Understanding; role; DNMT1; SUMOylation; Acute

Most cancers have abnormally high levels of DNA methylation, which turns off cell death genes, making cancer cells immortal. We have a new drug, called DNMT1i, that targets this feature of cancer cells and we recently found a new drug target that enhances the activity of DNMT1i. Our research will determine how these two drugs synergise to effectively kill cancer cells and will justify their use in clinical trials, which we believe will improve outcomes for patients with cancer.

大多数癌症都有异常高水平的DNA甲基化，这会关闭细胞死亡基因，使癌细胞永生。我们有一种名为DNMT1i的新药，它靶向癌细胞的这一特征，我们最近发现了一种新的药物靶点，可以增强DNMT1i的活性。我们的研究将确定这两种药物如何协同有效地杀死癌细胞，并证明它们在临床试验中的使用是合理的，我们相信这将改善癌症患者的预后。